

Product Data Sheet

Product Name: ABT-510 acetate

Cat. No.: GC70733

Chemical Properties

Cas. No. 442526-87-6


Formula $C_{48}H_{87}N_{13}O_{13}$ M.Wt 1054.28

Solubility H_2O : 100 mg/mL (94.85 mM; Need ultrasonic) Storage Sealed storage, away from moisture and light, under nitrogen

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD).

ABT-510 acetate (1, 5, 10, 20, 50 nM; 24 h) induces apoptosis in ID8 cells and increases the

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

incidence of apoptosis in the human epithelial cancer cell lines SKOV3, OVCAR3, and CAOV3^[1]. ABT-510 acetate (0-10 μ M; 7 days) inhibits NO-stimulated vascular cell outgrowth into and invasion through extracellular matrix. ABT-510 acetate blocks tumor-driven vascular cell outgrowth, NO-driven cGMP flux, and CD36-mediated fatty acid uptake. ^[3].

ABT-510 acetate (100 mg/kg; i.p.; single daily for 90 days) induces cells apoptosis *in vivo* and leads to a significant reduction in epithelial ovarian tumor size, ascites fluid volume, and secondary lesion dissemination in mice^[1].

ABT-510 acetate (60 mg/kg; osmotic minipumps for s.c.; single daily for 7 days) decreases angiogenesis and inflammation in a murine model of inflammatory bowel disease^[2].

References:

- [1]. Greenaway J, et.al. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. *Mol Cancer Ther.* 2009 Jan;8(1):64-74.
- [2]. Puneekar S, et.al. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. *Pathobiology.* 2008;75(1):9-21.
- [3]. Isenberg JS, et.al. Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. *Biochem Pharmacol.* 2008 Feb 15;75(4):875-82.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA